NCT04510636View on ClinicalTrials.gov

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 20, 2021

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
Classical Hodgkin LymphomaRelapsed CancerRefractory Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab is a intravenously administered humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

DRUG

Bendamustine Hydrochloride

Bendamustine is a unique alkylating agent with substantial activity in hematologic malignancies.

Trial Locations (1)

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER